Table 2.
Headache characteristics and treatment in randomized groups of 402 Norwegian patients referred to specialist for headache consulted by video or face-to-face.
| Baseline | 12-month follow-up | |||||
|---|---|---|---|---|---|---|
| Video (n = 200) | Face-to-face (n = 202) | p-value | Video (n = 151) | Face-to-face (n = 140) | p-value | |
| Onset of headache, age, mean (SD) | 24.5 (14.4) | 25.4 (14.3) | 0.533 | 24.4 (14.6) | 26.6 (15.2) | 0.203 |
| Headache duration, years, mean (SD) | 13.9 (13.0) | 12.4 (12.6) | 0.436 | 13.9 (12.7) | 13.5 (13.5) | 0.711 |
| HIT-6, mean (SD) | 64.1 (6.1) | 64.0 (6.1) | 0.824 | 63.7 (6.3) | 63.7 (6.1) | 0.988 |
| VAS, mean (SD) | 7.1 (2.2) | 6.9 (2.1) | 0.492 | 7.0 (2.2) | 6.9 (2.0) | 0.716 |
| Migraine, n (%)a | 106 (53.0) | 113 (55.9) | 0.617 | 79 (52.3) | 77 (55.0) | 0.724 |
| Tension-type headachea | 15 (7.5) | 8 (4.0) | 0.188 | 12 (7.9) | 5 (3.6) | 0.177 |
| Medication overuse headache (MOH)a | 35 (17.5) | 38 (18.8) | 0.826 | 27 (17.9) | 26 (18.6) | 1.0 |
| Drugs prescribed | ||||||
| Triptans, n (%) | 81 (40.5) | 75 (37.1) | 0.539 | 63 (41.7) | 49 (35.0) | 0.276 |
| NSAIDs, n (%) | 48 (24.0) | 61 (3.2) | 0.179 | 36 (23.8) | 41 (29.3) | 0.352 |
| Antihypertensive, n (%) | 33 (16.5) | 33 (16.3) | 1.0 | 27 (17.9) | 20 (14.3) | 0.429 |
| Antiepileptic, n (%) | 28 (14.0) | 23 (11.4) | 0.457 | 21 (13.9) | 16 (11.4) | 0.599 |
| Antidepressant, n (%) | 44 (22.0) | 56 (27.7) | 0.205 | 29 (19.2) | 39 (27.9) | 0.096 |
| Patients satisfied with consultation | 164 (82.0) | 150 (74.3) | 0.200 | 132 (87.4) | 123 (87.9) | 1.0 |
Baseline (n = 402) and 12-month follow-up data of 291 patients are presented with mean (SD) or numbers (%). BMI, body mass index; HIT-6, Headache Impact Test-6; NSAID, Non-Steroidal Anti-Inflammatory Drugs; VAS, visual analogue scale.
aMost prominent headache subtype given by specialist; SD, standard deviation.